AmacaThera Named Life Sciences Ontario Emerging Company of the Year
Recognition of AmacaThera’s leadership and landmark agreement with Pacira BioSciences for its long‑acting, opioid‑sparing anesthetic in post‑operative pain management
Progressing AMT-143 to Phase 2 clinical development in 2026
Toronto, Ontario – February 11, 2026 — AmacaThera, a leading developer of next-generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a wide range of active therapeutics, today announced that it has been named Emerging Company of the Year by Life Sciences Ontario. This award highlights AmacaThera’s evolution from an early-stage biotech into a global innovator, reflecting recognition from the broader life sciences community for its scientific excellence, innovative hydrogel technology, and increasing influence within the sector. This honor underscores the industry’s acknowledgement of AmacaThera’s promising advancements and the potential of its products to positively impact patient care.
